Clinical and Economic Considerations for a MAT Option
Webinar from June 7, 2018
Sponsored by Alkermes
Although medication-assisted treatment (MAT) is recommended as effective treatment for opioid dependence, its use has not kept pace with that of opioid dependence diagnoses. A MAT option associated with lower healthcare utilization and costs will be discussed. New studies regarding comparable efficacy, upon initiation of therapy, of some MAT options will also be reviewed.
Jeffrey A. Berman, MD, FASAM
Clinical Assistant Professor of Psychiatry, Department of Psychiatry
Rutgers Robert Wood Johnson Medical School
Medical Director, Department of Addition Psychiatry
SOBA College Recovery
Speakers are paid consultants of Alkermes, Inc. This is a non-CME presentation and is not eligible for CME credits.
This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.